The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm

Chemotherapy

Volumn 44, Issue 3, 1998, Pages 190-197

  Takeoka, Kaori ^a   Ichimiya, Tomoku ^a   Yamasaki, Tohru ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Biofilm; Chemiluminescence; Macrolides; Polymorphonuclear leukocytes; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROKITAMYCIN; ROXITHROMYCIN;

ARTICLE; BIOFILM; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0031896549     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007114     Document Type: Article

References (28)

1. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, Marrie TJ: Bacterial biofilms in nature and disease. Annu Rev Microbiol 1987;41:435-464.
2. Linker A, Jones RS: A new polysaccharide resembling alginic acid isolated from Pseudomonas. J Biol Chem 1966;241:3845-3851.
3. Evans LR, Linker A: Production and characterization of the slime polysaccharide of Pseudomonas aeruginosa. J Bacteriol 1973;116:915-924.
4. Costerton JW, Geesey GG, Cheng KJ: How bacteria stick. Sci Am 1978;238:86-95.
5. Buret A, Ward KH, Olson ME, Costerton JW: An in vitro model to study the pathobiology of infectious biofilms on biomaterial surfaces. J Biomed Mater Res 1991;25:865-874.
6. Baltimore RS, Mitchell M: Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: Comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains. J Infect Dis 1980; 141:238-247.
7. Bayer AS, Speert DP, Park S, Tu J, Witt M, Nast CC, Norman DC: Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa. Infect Immun 1991;59:302-308.
8. Jensen ET, Kharazmi A, Lam K, Costerton JW, Hoiby N: Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun 1990;58:2383-2385.
9. Jensen ET, Kharazmi A, Hoiby N, Costerton JW: Some bacterial parameters influencing the neutrophil oxidative burst response to Pseudomonas aeruginosa biofilms. APMIS 1992;100:727-733.
10. Ichimiya T, Yamasaki T, Nasu M: In vitro effect of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother 1994;34:331-341.
11. Bradley DE: A function of Pseudomonas aeruginosa PAO polar pili: Twitching motility. Can J Microbiol 1980;26:146-154.
12. Terry JM, Pina SE, Mattingly SJ: Environmental conditions which influence mucoid conversion in Pseudomonas aeruginosa PAO1. Infect Immun 1991;591:471-477.
13. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;21:77-89.
14. Kharazmi A, Hoiby N, Doering G, Valerius NH: Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun 1984;44:587-591.
15. Stiver HG, Zachidniak K, Speert DP: Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med 1988;11:247-252.
16. Pedersen SS, Kharazmi A, Espersen F, Hoiby N: Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun 1990;58:3363-3368.
17. Eftekhar F, Speert DP: Alginase treatment of mucoid Pseudomonas aeruginosa enhances phagocytosis by human monocyte-derived macrophages. Infect Immun 1988;56: 2788-2793.
18. Yamamoto M: The therapeutic effect of erythromycin on DPB: A double-blind comparative study. Annual Report on the Study of Diffuse Disseminated Disease (in Japanese). Tokyo, Ministry of Health and Welfare, 1992, pp 18-24.
19. Takeda H, Miura H, Kobayashi H: A study on long-term administration of TE-031 (clarithromycin) in patients with diffuse panbronchiolitis (in Japanese). Jpn J Infect Dis 1989;63:71-78.
20. Kobayashi H, Shimada K, Sano Y: Study on azithromycin in treatment of diffuse panbronchiolitis (in Japanese). Jpn J Infect Dis 1995;69:711-722.
21. Kobayashi H: Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99(suppl 6A):26S-30S.
22. Ras GJ, Anderson R, Taylor GW, Savage JE, Niekerk E, Joone G, Koornhof HJ, Saunders J, Wilson R, Cole PJ: Clindamycin, erythromycin, and roxithromycin inhibit the proinflammatory interactions of Pseudomonas aeruginosa pigments with human neutrophils in vitro. Antimicrob Agents Chemother 1992;36:1236-1240.
23. Anderson R: Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation. J Infect Dis 1989;159:966-973.
24. Nancy B, Esterly MD, Nancy L, Furey MD, Lillian E, Flanagan BS: The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978;70:51-55.
25. Miyachi Y, Yoshida A, Imamura S, Niwa Y: Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986;86: 449-453.
26. Fietta A, Bersani C, Santagada T, Bertoletti R, Grassi GG: In vitro activity of macrolides on human phagocytic functions. Chemioterapia 1987;6:52-56.
27. Ball AP: Azithromycin in the treatment of lower respiratory tract infections. Rev Contemp Pharmacother 1994;5:351-357.
28. Carlier MB, Zenebergh A, Tulkens PM: Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 1987;20 (suppl B):47-56.